Form 8-K - Current report:
SEC Accession No. 0001628280-21-021025
Filing Date
2021-11-01
Accepted
2021-11-01 17:25:27
Documents
13
Period of Report
2021-11-01
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20211101.htm   iXBRL 8-K 33075
  Complete submission text file 0001628280-21-021025.txt   191169

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20211101.xsd EX-101.SCH 2265
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20211101_def.xml EX-101.DEF 13058
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20211101_lab.xml EX-101.LAB 26049
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20211101_pre.xml EX-101.PRE 13936
6 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20211101_htm.xml XML 11025
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 211368394
SIC: 2834 Pharmaceutical Preparations